Dimensional Fund Advisors LP lowered its position in shares of Amedisys Inc. (NASDAQ:AMED) by 0.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,545,217 shares of the company’s stock after selling 7,350 shares during the period. Dimensional Fund Advisors LP owned about 4.61% of Amedisys worth $78,002,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Acrospire Investment Management LLC acquired a new position in shares of Amedisys during the first quarter valued at approximately $108,000. Teacher Retirement System of Texas raised its position in shares of Amedisys by 21.6% in the second quarter. Teacher Retirement System of Texas now owns 3,780 shares of the company’s stock valued at $191,000 after buying an additional 672 shares during the last quarter. Suntrust Banks Inc. raised its position in shares of Amedisys by 5.8% in the second quarter. Suntrust Banks Inc. now owns 4,480 shares of the company’s stock valued at $226,000 after buying an additional 246 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Amedisys during the first quarter valued at approximately $367,000. Finally, Legal & General Group Plc raised its position in shares of Amedisys by 19.4% in the first quarter. Legal & General Group Plc now owns 8,493 shares of the company’s stock valued at $408,000 after buying an additional 1,377 shares during the last quarter. 91.45% of the stock is owned by institutional investors and hedge funds.
Shares of Amedisys Inc. (NASDAQ:AMED) traded down 1.52% during mid-day trading on Monday, reaching $47.98. The company’s stock had a trading volume of 146,298 shares. The company has a market cap of $1.61 billion, a PE ratio of 41.98 and a beta of 1.05. Amedisys Inc. has a 52-week low of $31.16 and a 52-week high of $55.16. The company has a 50-day moving average price of $48.49 and a 200 day moving average price of $49.43.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.42 EPS for the quarter, hitting the consensus estimate of $0.42. Amedisys had a return on equity of 12.17% and a net margin of 2.78%. The firm had revenue of $360 million for the quarter, compared to the consensus estimate of $353.07 million. During the same quarter last year, the company earned $0.43 earnings per share. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. Equities analysts expect that Amedisys Inc. will post $1.69 earnings per share for the current year.
Several brokerages have recently commented on AMED. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Zacks Investment Research lowered Amedisys from a “hold” rating to a “sell” rating in a report on Monday, July 11th. Stephens began coverage on Amedisys in a report on Thursday, June 16th. They set an “equal weight” rating and a $55.00 price objective for the company. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $51.75.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.
Receive News & Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.